The future of patient-derived tumor xenografts in cancer treatment
| العنوان: | The future of patient-derived tumor xenografts in cancer treatment |
|---|---|
| المؤلفون: | Agrin Moeini, Daniela Sia, Augusto Villanueva, Ismail Labgaa |
| المصدر: | Pharmacogenomics. 16:1671-1683 |
| بيانات النشر: | Future Medicine Ltd, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Pharmacology, Oncology, medicine.medical_specialty, business.industry, Cancer, medicine.disease, Precision medicine, Xenograft Model Antitumor Assays, Cancer treatment, Clinical trial, Mice, Therapeutic approach, Internal medicine, Biomarkers, Tumor, Genetics, Animals, Heterografts, Humans, Molecular Medicine, Medicine, Personalized medicine, Precision Medicine, business, Neoplasm Transplantation |
| الوصف: | Over the last decades, major technological advancements have led to a better understanding of the molecular drivers of human malignancies. Nonetheless, this progress only marginally impacted the cancer therapeutic approach, probably due to the limited ability of experimental models to predict efficacy in clinical trials. In an effort to offset this limitation, there has been an increasing interest in the development of patient-derived xenograft (PDX) models where human tumors are xenotransplanted into immunocompromised mice. Considering their high resemblance to human tumors and their stability, PDX models are becoming the preferred translational tools in preclinical studies. Nonetheless, several limitations hamper a wider use of PDX models and tarnish the concept that they might represent the missing piece in the personalized medicine puzzle. |
| تدمد: | 1744-8042 1462-2416 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f7c3388a388326689b64854d396c33 https://doi.org/10.2217/pgs.15.102 |
| رقم الأكسشن: | edsair.doi.dedup.....79f7c3388a388326689b64854d396c33 |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 17448042 14622416 |
|---|